• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.

作者信息

Ziff Monica, Lawson Gabrielle, De-Silva Dunnya, Cheesman Simon, Kyriakou Charalampia, Mahmood Shameem, Papanikolaou Xenofon, Rabin Neil, Sachchithananthan Sajitha, Sive Jonathan, Wechalekar Ashutosh, Yong Kwee, Popat Rakesh

机构信息

University College London Hospitals NHS Foundation Trust, London, UK.

出版信息

Leuk Lymphoma. 2021 May;62(5):1243-1246. doi: 10.1080/10428194.2020.1864356. Epub 2021 Jan 13.

DOI:10.1080/10428194.2020.1864356
PMID:33439062
Abstract
摘要

相似文献

1
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.伊沙佐米联合来那度胺和地塞米松治疗复发多发性骨髓瘤患者：来自真实世界数据集的17p缺失影响及对蛋白酶体抑制剂的敏感性
Leuk Lymphoma. 2021 May;62(5):1243-1246. doi: 10.1080/10428194.2020.1864356. Epub 2021 Jan 13.
2
Ixazomib in the management of relapsed multiple myeloma.伊沙佐米在复发性多发性骨髓瘤中的治疗作用。
Future Oncol. 2018 Aug;14(20):2013-2020. doi: 10.2217/fon-2017-0710. Epub 2018 Feb 22.
3
Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.伊沙佐米、来那度胺和地塞米松联合用药用于复发/难治性多发性骨髓瘤患者的“真实世界”临床实践
Ann Hematol. 2022 Jan;101(1):81-89. doi: 10.1007/s00277-021-04663-0. Epub 2021 Sep 22.
4
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.来那度胺或蛋白酶体抑制剂既往暴露对复发/难治性多发性骨髓瘤患者接受伊沙佐米-来那度胺-地塞米松治疗效果的影响：来自 INSURE 研究的 pooled 分析。
Eur J Haematol. 2024 Aug;113(2):190-200. doi: 10.1111/ejh.14214. Epub 2024 Apr 23.
5
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.随机、双盲、安慰剂对照的 III 期研究，评估伊沙佐米联合来那度胺-地塞米松治疗复发/难治性多发性骨髓瘤患者：中国延续研究。
J Hematol Oncol. 2017 Jul 6;10(1):137. doi: 10.1186/s13045-017-0501-4.
6
Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.在德国，接受蛋白酶体抑制剂治疗的复发性/难治性多发性骨髓瘤患者的特征和结局。
Oncol Res Treat. 2020;43(9):449-459. doi: 10.1159/000509018. Epub 2020 Jul 21.
7
[Analysis of the efficacy and survival of ixazomib-containing regimens in patients with refractory and relapsed multiple myeloma].含伊沙佐米方案治疗难治性和复发性多发性骨髓瘤患者的疗效及生存分析
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):680-684. doi: 10.3760/cma.j.issn.0253-2727.2022.08.011.
8
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.在常规临床实践中，来那度胺和地塞米松（Rd）与伊沙佐米、来那度胺和地塞米松（IRD）相比，对复发和难治性多发性骨髓瘤患者的生存获益。
BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1.
9
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.来那度胺联合伊沙佐米和地塞米松治疗复发/难治性多发性骨髓瘤的真实世界疗效。
Future Oncol. 2021 Jul;17(19):2499-2512. doi: 10.2217/fon-2020-1225. Epub 2021 Mar 26.
10
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.在未经治疗的多发性骨髓瘤患者中，口服蛋白酶体抑制剂伊沙佐米与来那度胺和地塞米松联合使用的安全性和耐受性：一项开放标签的 1/2 期研究。
Lancet Oncol. 2014 Dec;15(13):1503-1512. doi: 10.1016/S1470-2045(14)71125-8. Epub 2014 Nov 14.

引用本文的文献

1
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature.伊沙佐米-来那度胺-地塞米松（IRd）用于复发难治性多发性骨髓瘤（RRMM）——来自德国的多中心真实世界分析及文献比较综述
Ann Hematol. 2025 Jun 5. doi: 10.1007/s00277-025-06441-8.
2
Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.基于来那度胺联合地塞米松方案治疗初治多发性骨髓瘤的真实世界研究。
Cancer Med. 2024 May;13(9):e7177. doi: 10.1002/cam4.7177.
3
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
伊沙佐米、来那度胺和地塞米松用于复发和难治性多发性骨髓瘤的常规临床实践：延长随访分析及后续治疗结果
Cancers (Basel). 2022 Oct 21;14(20):5165. doi: 10.3390/cancers14205165.
4
[The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].伊沙佐米/来那度胺/地塞米松治疗复发/难治性多发性骨髓瘤的疗效和安全性：一项中国多中心真实世界研究
Zhonghua Xue Ye Xue Za Zhi. 2021 Aug 14;42(8):628-634. doi: 10.3760/cma.j.issn.0253-2727.2021.08.003.